In my previous earnings estimate analysis, I reached the conclusion that Teva Pharmaceutical (NYSE:TEVA) could not possibly meet its guidance. The specific problem I had was accounting for its revenue guidance of $6.2 to $6.5 billion. The article sparked a debate with one of the commentators which then continued for several days in private. This was a perfect example of my motive (written on my bio/profile page) to write for Seeking Alpha in the first place: "I use Seeking Alpha to correct myself not only through editors but also through commentators".
Now, I think that my previous estimates were wrong and that it is quite possible for the company to meet its guidance. This follow-up piece will explain why. Being wrong hurts the ego a tad bit, but having the accuracy to make money more than makes up for that.
